John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses new agents under development for the treatment of chronic lymphocytic leukemia (CLL), including next-generation BTK and Bcl-2 inhibitors, bispecific antibodies, and CAR-T therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.